dactinomycin has been researched along with Hypersensitivity, Type III in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gabrielsen, AE; Olsen, CT | 1 |
| Gabrielsen, AE; Olsen, CT; Rudofsky, UH; Simmons, AD; Urizar, RE | 1 |
2 other study(ies) available for dactinomycin and Hypersensitivity, Type III
| Article | Year |
|---|---|
Dactinomycin treatment of murine lupus erythematosus. II. Dose and schedule of administration.
Topics: Animals; Dactinomycin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Immune Complex Diseases; Kidney Diseases; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Proteinuria | 1980 |
Dactinomycin treatment of murine lupus erythematosus. I. Renal disease and longevity.
Topics: Animals; Antigen-Antibody Complex; Dactinomycin; Disease Models, Animal; Fluorescent Antibody Technique; Glomerulonephritis; Immune Complex Diseases; Lupus Erythematosus, Systemic; Mice; Microscopy, Electron | 1978 |